March 20th, 2023
Adragos Pharma acquires Clinigen’s development unit, Lamda Laboratories in Greece, Athens
Adragos Pharma GmbH has signed a definitive agreement with global pharmaceutical services company Clinigen Limited to acquire Lamda Laboratories S.A. in Athens. The acquisition of Lamda Laboratories significantly expands Adragos' pharmaceutical product development, regulatory affairs and supply chain management services for its global pharmaceutical customers.
March 2nd, 2023
Successful transaction: Adragos Pharma has officially taken over the Sanofi production site in Kawagoe, Japan
Adragos Pharma GmbH successfully completed the acquisition of one of Japan's leading pharmaceutical manufacturing facilities from Sanofi K.K. The transaction makes Adragos Pharma the third largest pure-play contract manufacturer in Japan, one of its three core markets. The acquisition also kicks off a long-term supply agreement between the CDMO and Sanofi. Kawagoe Pharma will continue to produce for Sanofi and the Japanese market as a strategic partner, thus playing an essential role for the local healthcare system.
October 13th, 2022
Adragos Pharma to acquire Sanofi’s manufacturing site in Kawagoe, Japan
Adragos Pharma, a rapidly growing pharmaceutical Contract Development and Manufacturing Organization (CDMO) based in Munich, Germany, signed definitive agreements with Sanofi K.K. for the acquisition of a pharmaceutical manufacturing site in Kawagoe, close to Tokyo, Japan. Adragos Pharma will also enter into a long-term supply agreement with Sanofi K.K, thereby becoming a strategic partner for Sanofi in the Japanese market. Furthermore, Adragos Pharma will introduce new customers to the manufacturing site from Europe, North America as well as the domestic Japanese market. Their second investment in the region, Adragos Pharma will now rank among the Top 3 largest pure-play CDMOs in Japan.
August 9th, 2021
FSN Capital VI partners with Prange Group to accelerate growth of Adragos Pharma
FSN Capital VI has acquired a majority share in Adragos Pharma Group, a growing B2B contract developer and manufacturer (CDMO) for pharmaceuticals. The current owner, Prange Group, remains invested to support Adragos’ journey towards a leading global position in the highly attractive and well-protected pharmaceutical CDMO market.